Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
80000.000.1996%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Quoin Pharmaceuticals Ltd

QNRXNASDAQ
Trade with Public
Trade with Public
$7.26
-0.61-7.75%
At close: Sep 4, 5:00 PM EST
$7.11
-0.15-2.07%
After Hours: Sep 4, 5:11 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Quoin Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Quoin Pharmaceuticals (QNRX).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$17Upside to Avg. PT+139.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 4, 2026LUCID CAPITAL MARKETSDev Prasad InitiateBuy$30
Mar 15, 2024Maxim GroupNaz RahmanPT CutBuy$15→$4

Analyst Ratings News

PRO
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $30.
Benzinga Newsdesk

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

Benzinga Insights

PRO
Maxim Group Maintains Buy on Quoin Pharmaceuticals, Lowers Price Target to $4

Maxim Group analyst Naz Rahman maintains Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy and lowers the price target from $15 to $4.
Benzinga Newsdesk

Watching Quoin Pharmaceuticals; Zacks Small-Cap Research Sets $4 Price Target

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_03222023_QNRX_Marin.pdf
Happy Mohamed

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022

Upgrades
Benzinga Insights

PRO
Alliance Global Partners Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20

Alliance Global Partners analyst James Molloy initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved